Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERILE WATER FOR INJECTION vs PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Water serves as a vehicle for dissolving or diluting drugs for parenteral administration; it has no intrinsic pharmacologic activity. It maintains body fluid balance and is essential for cellular homeostasis.
PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.
Vehicle for reconstitution of parenteral drugs,Fluid replacement in patients with isotonic fluid deficits when used with appropriate electrolytes (e.g., 5% dextrose in water),Off-label: Diluent for irrigation solutions
Peritoneal dialysis for patients with end-stage renal disease,Correction of fluid and electrolyte imbalances,Correction of metabolic acidosis
Sterile water for injection is not administered directly; it is used as a diluent or solvent for medications. There is no standard therapeutic dose. Administration is via intravenous, intramuscular, or subcutaneous route as required for reconstitution.
Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.
The elimination half-life of water is approximately 7-14 days in healthy adults, reflecting the turnover rate of total body water (TBW). In clinical use, administered water equilibrates rapidly with TBW (half-life <1 hour) and is then subject to normal renal excretion, with a terminal half-life of 7-14 days as part of body water turnover. Clinically, water is not considered to have a meaningful elimination half-life due to rapid equilibration and homeostatic regulation.
Terminal elimination half-life is approximately 0.5–1 hour in patients with normal renal function. In end-stage renal disease (ESRD), half-life extends to 6–8 hours, requiring dose adjustment.
Water is not metabolized; it is distributed in the body and excreted primarily by the kidneys via urine, with minor losses through skin, lungs, and feces.
Bicarbonate and lactate are metabolized in the liver and kidneys. Lactate is converted to bicarbonate via hepatic gluconeogenesis and the Cori cycle.
Renal excretion of free water following equilibration with total body water; no active elimination. >99% eliminated via kidneys as urine, with minor losses via insensible routes (skin, lungs) and feces (<1% combined).
Renal: 100% (proximal tubular secretion and glomerular filtration). Biliary/fecal: negligible (<1%).
0%. Water does not bind to plasma proteins. It is freely diffusible across capillary and cell membranes.
Approximately 10–20% bound to albumin. Binding is low and clinically insignificant.
Approximately 0.55-0.60 L/kg in adults (total body water: ~42 L in 70 kg). This represents the volume of fluid into which water distributes, essentially the total body water compartment. In clinical pharmacokinetics, Vd is not applicable for water as it is the solvent of the body.
Volume of distribution is 0.2–0.3 L/kg (10–20 L in adults), approximating extracellular fluid volume. This small Vd is consistent with limited tissue penetration.
Intravenous: 100%. Subcutaneous: ~100% (water is absorbed completely due to small molecular size and passive diffusion). Oral: ~100% (water is absorbed from gastrointestinal tract via osmosis and aquaporins, with negligible first-pass metabolism).
Intravenous: 100% (only route of administration).
No dose adjustment is needed for renal impairment as sterile water for injection is not systemically active and is used solely as a vehicle.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of hyperphosphatemia and hyperkalemia. In mild to moderate impairment (e GFR 30-89): reduce dose by 25-50% and monitor serum potassium and phosphate levels.
No dose adjustment is needed for hepatic impairment as sterile water for injection is not systemically active and is used solely as a vehicle.
No specific dose adjustment recommended for Child-Pugh class A or B. For Child-Pugh class C: use with caution and consider reducing dose by 25% due to potential for altered phosphate metabolism and encephalopathy risk.
Weight-based dosing is not applicable; used as a diluent per medication-specific instructions. Volume of sterile water for injection should be adjusted based on the required dose of the reconstituted drug and the patient's weight and clinical condition.
Dose based on body weight: 1-2 mmol/kg/day of potassium phosphate intravenously as part of parenteral nutrition, with infusion rate not exceeding 0.5 mmol/kg/hour. Maximum daily dose: 4 mmol/kg.
No specific dose adjustment needed for elderly patients; use the minimal volume necessary to achieve desired drug concentration, considering potential fluid and electrolyte imbalances and reduced renal function.
Start at lower end of dosage range (e.g., 20-30 mmol/day) due to age-related renal function decline. Monitor renal function and serum electrolytes closely; adjust dose based on creatinine clearance.
For sterile water for injection: Do not use for intravenous injection without first adjusting isotonicity, as administration of free water into the bloodstream can cause severe hemolysis and potentially fatal complications.
None.
Risk of hemolysis and electrolyte imbalance when administered intravenously without addition of solutes; monitor for fluid overload and hyponatremia; caution in patients with impaired renal function, cardiac failure, or conditions predisposing to fluid retention.
Peritonitis risk,Catheter-related infections,Fluid and electrolyte disturbances,Metabolic alkalosis (with high bicarbonate levels),Hypokalemia or hyperkalemia,Peritoneal membrane failure
Absolute: None. Relative: Severe renal impairment (risk of volume overload), known hypersensitivity to any component (if present in the container), and conditions where saline or electrolyte-containing solutions are required.
Hypersensitivity to any component,Pre-existing severe metabolic alkalosis,Documented peritoneal membrane failure,Abdominal or peritoneal defects (e.g., hernias, fistulas),Uncorrected mechanical defects in peritoneal cavity
No known food interactions. Sterile water for injection is intended for parenteral administration only and does not interact with dietary items.
No direct food interactions, but dietary intake of potassium, calcium, and phosphorus must be managed per clinical guidelines during CRRT. Avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless potassium supplementation is adjusted accordingly.
No fetal risk identified; sterile water for injection is isotonic and lacks pharmacological activity. No known teratogenic effects in any trimester.
No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or electrolyte imbalances may pose risks. First trimester: theoretical risk of teratogenicity only with severe maternal hyperphosphatemia. Second/third trimesters: risks include fetal hyperphosphatemia, hypocalcemia, and potential soft tissue calcification. Use only if clearly needed.
Safe for use during breastfeeding. Sterile water for injection is a normal constituent of breast milk; M/P ratio not applicable.
Potassium phosphate is present in human milk at levels consistent with physiological requirements. Milk-to-plasma ratio not established. Exogenous phosphate is rapidly absorbed and may cause hyperphosphatemia in the infant at high maternal doses. Caution advised; monitor infant for signs of hyperphosphatemia (e.g., hypocalcemia, tetany).
No dose adjustment required; pharmacokinetics of water are not altered in pregnancy.
Physiologic increase in plasma volume and glomerular filtration rate in pregnancy may increase phosphate clearance, potentially requiring higher doses to maintain therapeutic levels. However, individualize dosing based on serum phosphate monitoring. No standard dose modification; adjust per clinical response and lab values.
Sterile water for injection is hypotonic and must not be administered intravenously without first being made isotonic by admixture with appropriate solutes (e.g., dextrose, saline) to prevent hemolysis. It is used for reconstitution of powdered medications and for dilution of concentrated solutions. Always verify compatibility with other drugs before mixing. Use immediately after opening; discard any unused portion as it contains no preservatives.
PHOXILLUM B22K 4/0 is a bicarbonate-buffered, low-calcium dialysate for continuous renal replacement therapy (CRRT). Monitor serum potassium closely as it contains 4 m Eq/L K+, 0 m Eq/L Ca2+, and 22 m Eq/L bicarbonate. Use with caution in hyperkalemic patients; may require adjustment of potassium supplementation. Ensure adequate calcium replacement via separate infusion to avoid hypocalcemia. Verify compatibility with other IV fluids and medications administered through the CRRT circuit.
This product is sterile water; do not inject it directly into a vein unless mixed with other medications as directed.,It is used to dissolve or dilute other medicines before injection.,Your healthcare provider will prepare and administer this product; do not attempt to self-administer.,Tell your pharmacist or nurse if you have any allergies or medical conditions.,Store at room temperature; do not freeze.
This solution is used only during continuous dialysis in the hospital setting; it is not for direct infusion into your vein.,Your healthcare team will monitor your blood potassium and calcium levels closely while you receive this treatment.,Do not eat or drink anything unless your doctor or nurse approves, as your diet may need to be adjusted.,Report any muscle cramps, tingling, or irregular heartbeat to your nurse immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERILE WATER FOR INJECTION vs PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, answered by our medical review team.
STERILE WATER FOR INJECTION is a Irrigation Solution that works by Water serves as a vehicle for dissolving or diluting drugs for parenteral administration; it has no intrinsic pharmacologic activity. It maintains body fluid balance and is essential for cellular homeostasis.. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is a Irrigation Solution that works by PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERILE WATER FOR INJECTION and PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERILE WATER FOR INJECTION is: Sterile water for injection is not administered directly; it is used as a diluent or solvent for medications. There is no standard therapeutic dose. Administration is via intravenous, intramuscular, or subcutaneous route as required for reconstitution.. The standard adult dose of PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is: Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERILE WATER FOR INJECTION and PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERILE WATER FOR INJECTION is classified as Category C. No fetal risk identified; sterile water for injection is isotonic and lacks pharmacological activity. No known teratogenic effects in any trimester.. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is classified as Category C. No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or elect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.